Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Experts Discuss Guidelines for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease

Ruth Jessen Hickman, MD  |  Issue: March 2025  |  March 6, 2025

Screening & Monitoring for ILD

Click to enlarge.

To help with screening decisions, the first guideline provides a detailed list of disease-specific factors that may increase a patient’s risk of developing ILD, drawing on elements from a patient’s medical history, current presentation and laboratory results.1 Patients who lack the risk factors and are asymptomatic may not necessarily need screening beyond their regular history and physical exam (see Figure 1).

“If clinicians are uncertain whether a patient should be screened or not, they should err on the side of caution and screen,” says Dr. Johnson.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

One recommendation: Pulmonary function tests (PFTs) are conditionally recommended over history and physical exam or ambulatory desaturation testing alone to screen for ILD in SARD patients at higher risk.

Others conditional recommendations are for high-resolution computed tomography (HRCT) of the chest over PFTs alone, and for HRCT over history and physical exam, as well as in favor of chest HRCT with PFTs over PFTs alone.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Bernstein has a strong preference for screening all people who have SSc with HRCT at presentation, due to the high prevalence of the disease in this population and the fact that PFTs alone may miss early ILD.

Click to enlarge.

The Patient Panel expressed a strong preference for early diagnosis of ILD, even if more frequent screening leads to identification of subclinical disease or incidental findings that may require further testing.

Once diagnosed with ILD, SARD patients require monitoring for their response to therapy, typically in conjunction with pulmonology. The Patient Panel strongly preferred more frequent testing over less frequent testing to avoid missing signs of progression.

Treatment of ILD in SARDs

Most recommendations in the treatment guideline were based on low or very low certainty of evidence, as were the recommendations on screening and monitoring treatment. Dr. Johnson points out that in these circumstances, patients’ preferences and values more strongly influence treatment choice. “The Patient Panel told us they wanted clear communication about the advantages and side effects [of therapies], so they could be actively involved in their choice of medication,” she says.

Click to enlarge.

The guideline recommendations are stratified by first-line treatments (see Figure 2) vs. treatments to consider if a patient’s disease has progressed after initial treatment, with certain recommendations specific to individual SARDs (see Figure 3). Additional recommendations clarify additional treatment approaches in patients with rapidly progressing disease (see Figure 4).

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceSjögren’s DiseaseSystemic Sclerosis Tagged with:Interstitial Lung Diseaseinterstitial lung disease (ILD)

Related Articles
    Editor's Pick

    The ACR and CHEST Release 2 New ILD Guidelines

    July 9, 2024

    Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).

    What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

    December 1, 2012

    Patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing connective tissue disease-associated interstitial lung disease (CTD-ILD)
     

    Gajus/shutterstock.com

    Guidelines for ILD in Systemic Autoimmune Rheumatic Diseases

    December 4, 2023

    SAN DIEGO—In a scientific session at ACR Convergence 2023, Sindhu Johnson, MD, PhD, and Dinesh Khanna, MD, MSc, discussed ACR’s new guideline on SARDs and ILD.

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences